Biodegradable Pickering emulsions of Lipiodol for liver trans-arterial chemo-embolization.


Journal

Acta biomaterialia
ISSN: 1878-7568
Titre abrégé: Acta Biomater
Pays: England
ID NLM: 101233144

Informations de publication

Date de publication:
15 03 2019
Historique:
received: 20 09 2018
revised: 15 01 2019
accepted: 28 01 2019
pubmed: 2 2 2019
medline: 9 4 2020
entrez: 2 2 2019
Statut: ppublish

Résumé

Water-in-oil (W/O) Lipiodol emulsions remain the preferable choice for local delivery of chemotherapy in the treatment of hepatocellular carcinoma. However, their low stability severely hampers their efficiency. Here, remarkably stable W/O Lipiodol emulsion stabilized by biodegradable particles was developed thanks to Pickering technology. The addition of poly(lactide-co-glycolide) nanoparticles (NPs) into the aqueous-phase of the formulation led to W/O Pickering emulsion by a simple emulsification process through two connected syringes. Influence of nanoparticles concentration and water/oil ratio on emulsion stability and droplet size were studied. All formulated Pickering emulsions were W/O type, stable for at least one month and water droplets size could be tuned by controlling nanoparticle concentration from 24 µm at 25 mg/mL to 69 µm at 5 mg/mL. The potential of these emulsions to efficiently encapsulate chemotherapy was studied through the internalization of doxorubicin (DOX) into the aqueous phase with a water/oil ratio of 1/3 as recommended by the medical community. Loaded-doxorubicin was released from conventional emulsion within a few hours whereas doxorubicin from stable Pickering emulsion took up to 10 days to be completely released. In addition, in vitro cell viability evaluations performed on the components of the emulsion and the Pickering emulsion have shown no significant toxicity up to relatively high concentrations of NPs (3 mg/mL) on two different cell lines: HUVEC and HepG2. STATEMENT OF SIGNIFICANCE: We present an original experimental research in the field of nanotechnology for biomedical applications. In particular, we have formulated, thanks to Pickering technology, a new therapeutic emulsion stabilized with biodegradable PLGA nanoparticles. As far as we know, this is the first therapeutic Pickering emulsion reported in the literature for hepatocellular carcinoma. Such a new emulsion allows to easily prepare a predictable and stable lipiodolized emulsion having all the required characteristics for optimum tumor uptake. As demonstrated throughout our manuscript, emulsions stabilized with these nanoparticles have the advantage of being biodegradable, biocompatible and less toxic compared to usual emulsions stabilized with synthetic surfactants. These findings demonstrate the plausibility of the use of Pickering emulsions for chemoembolization as a therapeutic agent in extended release formulations.

Identifiants

pubmed: 30708065
pii: S1742-7061(19)30076-5
doi: 10.1016/j.actbio.2019.01.054
pii:
doi:

Substances chimiques

Delayed-Action Preparations 0
Emulsions 0
Polyesters 0
poly(lactide) 459TN2L5F5
Ethiodized Oil 8008-53-5
Doxorubicin 80168379AG

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

177-186

Informations de copyright

Copyright © 2019 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Auteurs

Frédéric Deschamps (F)

Département de Radiologie Interventionnelle, Gustave Roussy, Université Paris-Saclay, 114 rue Edouard Vaillant, 94805 Villejuif, France; Laboratoire de vectorologie et thérapeutiques anticancéreuses, UMR8203, Université Paris-Saclay, 94805 Villejuif, France.

Thomas Isoardo (T)

Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Stéphanie Denis (S)

Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Nicolas Tsapis (N)

Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Lambros Tselikas (L)

Département de Radiologie Interventionnelle, Gustave Roussy, Université Paris-Saclay, 114 rue Edouard Vaillant, 94805 Villejuif, France; Laboratoire de vectorologie et thérapeutiques anticancéreuses, UMR8203, Université Paris-Saclay, 94805 Villejuif, France.

Valérie Nicolas (V)

Plateforme d'imagerie cellulaire MIPSIT, SFR-UMS-IPSIT, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Angélo Paci (A)

Laboratoire de vectorologie et thérapeutiques anticancéreuses, UMR8203, Université Paris-Saclay, 94805 Villejuif, France; Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Elias Fattal (E)

Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Thierry de Baere (T)

Département de Radiologie Interventionnelle, Gustave Roussy, Université Paris-Saclay, 114 rue Edouard Vaillant, 94805 Villejuif, France; Laboratoire de vectorologie et thérapeutiques anticancéreuses, UMR8203, Université Paris-Saclay, 94805 Villejuif, France.

Nicolas Huang (N)

Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

Laurence Moine (L)

Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France. Electronic address: laurence.moine@u-psud.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH